Drugs / Contraloid
Contraloid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT04711486 | Dec 2020 → Jan 2022 | Alzheimer disease | Charite University, Berlin, Germany | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03955380 Comparator | Dec 2018 → Apr 2019 | Alzheimer disease | Prof. Dr. Dieter Willbold | Completed | No outcome recorded |
| Phase 1 | NCT03944460 Comparator | Apr → Jul 2018 | Alzheimer disease | Prof. Dr. Dieter Willbold | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Priavoid | Results Priavoid Presents Initial Phase 2 Data Suggesting Favorable Safety Profile for Alzheimer’s Candidate PRI-002 at AD/PD™ 2026 priavoid.com ↗
Priavoid GmbH (“Priavoid”) today announced promising initial safety data from its ongoing Phase 2 trial (PRImus-AD, NCT06182085 ) evaluating its lead candidate, PRI-002, for the treatment of Alzheimer’s disease (AD). |
| 2026-03-05 | Priavoid | Results Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘s and Preclinical PoC for Parkinson‘s Programs at AD/PD™ 2026 priavoid.com ↗
The results indicate a favorable safety and tolerability profile, particularly regarding Amyloid-Related Imaging Abnormalities (ARIA). |
| 2023-11-20 | Priavoid | Regulatory New Alzheimer’s drug PRI-002 receives EMA approval for Phase II study priavoid.com ↗
Priavoid GmbH and PRInnovation GmbH announce today that the European Medicines Agency (EMA) has granted approval to conduct a Phase II clinical trial for the drug candidate PRI-002 to combat Alzheimer’s disease. |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Contraloid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04711486 ↗ |
| Known as | Contraloid acetate | “The investigation on the compound Contraloid acetate in a multiple-ascending-dose phase I study has been performed in 24 healthy male participants” NCT03955380 ↗ |
| Known as | RD2 | “Contraloid (alias RD2, alias PRI-002) is an all-D-peptide, which was developed to directly destroy toxic and replicating A-beta oligomer prions, by disassembling them into...” NCT03955380 ↗1“The study drug Contraloid (alias RD2, alias PRI-002) is an orally available all-D-peptide” NCT03944460 ↗ |
| Modality | Peptide | “an orally available all-D-peptide” NCT03944460 ↗ |
| Route | Oral | “administered orally” NCT03944460 ↗ |